Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 8/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 8/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 8/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194784 | 1.00 | CACNA1F (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL6955134 | 0.82 | POLB (0.68) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL7416441 | 0.79 | POLB (0.64) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL7132512 | 0.79 | POLB (0.75) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL7341750 | 0.76 | CACNA1F (0.70) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL10670264 | 0.75 | KMT2A (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL10666490 | 0.75 | CACNA1F (0.57) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL7274108 | 0.74 | CACNA1F (0.75) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL10918103 | 0.73 | MAPT (0.70) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL9675181 | 0.73 | MEN1 (0.70) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | CACNA1F 82/4885CACNA1D 77/4885CACNA1S 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.